About us Contacts Drug interactions: 390 212
Drug search by name

Abemaciclib and Empagliflozin and Metformin Extended-Release Tablets

Determining the interaction of Abemaciclib and Empagliflozin and Metformin Extended-Release Tablets and the possibility of their joint administration.

Check result:
Abemaciclib <> Empagliflozin and Metformin Extended-Release Tablets
Relevance: 01.11.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Abemaciclib may increase the blood levels and effects of metFORMIN. You may need a dose adjustment or closer monitoring of your blood sugar to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects such as nausea, vomiting, diarrhea, flatulence, and indigestion. You should seek immediate medical attention if you develop weakness, muscle pain, chills, increasing drowsiness, abdominal pain or discomfort, slow or irregular heartbeat, breathing difficulty and other unusual symptoms, as these may be early signs of a rare but serious side effect of metFORMIN known as lactic acidosis. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration with abemaciclib may increase the plasma concentrations of metformin. The proposed mechanism is abemaciclib inhibition of OCT 2, MATE 1 and MATE 2-K, the renal transporters involved in the active tubular secretion of metformin. In healthy study subjects, administration of a single 1000 mg dose of metformin with a single 400 mg dose of abemaciclib (2.7 times the approved recommended dose of 150 mg) increased metformin peak plasma concentration (Cmax) and systemic exposure (AUC) by 22% and 37%, respectively, compared to metformin administered alone. Abemaciclib also reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, without any effect on glomerular filtration rate (GFR).

MANAGEMENT: Caution is advised when metformin is used with abemaciclib. Dose adjustments of metformin as well as clinical and laboratory monitoring of glycemic control may be appropriate whenever abemaciclib is added to or withdrawn from therapy. Patients should be advised to be alert to potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitations, and tachycardia.

References
  • "Product Information. Verzenio (abemaciclib)." Lilly, Eli and Company, Indianapolis, IN.
Abemaciclib

Generic Name: abemaciclib

Brand name: Verzenio

Synonyms: n.a.

Empagliflozin and Metformin Extended-Release Tablets

Generic Name: empagliflozin / metformin

Brand name: Synjardy, Synjardy XR

Synonyms: Empagliflozin and metformin, Empagliflozin and Metformin

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.